TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05985694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.
Study: NCT05249972
Drug: AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cutaneous spray
Study: NCT05249972
Drug: Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
Normalized name: Enstilar Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical foam
Study: NCT04849364
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 BID Orally 14 days on and 7 days off Cycle = 21 days; Total of 8 cycles
Study: NCT00006488
Drug: recombinant-methionyl human glial cell line-derived neurotrophic factor
Normalized name: brain-derived neurotrophic factor, human
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06596291
Drug: EG110A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants treated with EG110A
Study: NCT05591222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously as two injections for each dose.
Study: NCT04199572
Drug: Diclofenac and Paracetamol
Normalized name: Diclofenac and paracetamol and serrapeptase only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo
Study: NCT04862962
Drug: Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets 10 mg/10 mg or 20 mg/10 mg
Study: NCT06614751
Drug: DAT-2645 tablet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.
Study: NCT06614751
Drug: DAT-2645 tablet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study set 6 dose level cohorts in dose escalation part.On C0D1, patient take DAT-2645 one time (Single use), The dosage is same as his enrolled cohort dose level. if no DLT, 7 days later(C1D1), patients will continue taking DAT-2645 tablet daily, dasage is same as before, 21days/cycle.
Study: NCT05186779
Drug: Progestagen
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer
Study: NCT05143502
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Prednisolone 40 mg/day for two weeks.
Study: NCT05105919
Drug: Aspirin 80 mg EC Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a 7 day supply of Aspirin 80 mg EC Tab and will be instructed to take the drug at the same time every day for 7 days.
Study: NCT05387070
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
Study: NCT04968106
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
Study: NCT04968106
Drug: INCMGA00012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles
Study: NCT05945667
Drug: Monural
Normalized name: Monuril Paediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 sachet, only 1st day of trial
Study: NCT04926545
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
Study: NCT05919745
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative delivery of ibuprofen per os.
Study: NCT05919745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative delivery of placebo per os.
Study: NCT05919745
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
Study: NCT04767087
Drug: Nigella sativa seed
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/Kg/day
Study: NCT06615700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of NA-931
Study: NCT05896215
Drug: KNP2002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy topical administration for 12 weeks
Study: NCT05896215
Drug: Placebo of KNP2002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy topical administration for 12 weeks
Study: NCT05453786
Drug: SID1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of SID1903 after an overnight fast
Study: NCT05453786
Drug: SID1903-R1/SID1903-R2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
Study: NCT05345782
Drug: MARCAINE AND BETAMETHAZONE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic Hypo gastric Neural Plexus Block
Study: NCT05345782
Drug: MARCAINE AND BETAMETHAZONE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block
Study: NCT05227131
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (1000 mg per square meter of body-surface area) will be administrated orally twice daily on days 1 to 14 of each 21-day cycle
Study: NCT06123338
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks
Study: NCT06598631
Drug: Volenrelaxin
Normalized name: Volenrelaxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06598631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05190523
Drug: ASC42 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of ASC42 tablets orally once daily for 12 weeks.
Study: NCT05190523
Drug: ASC42 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of ASC42 tablets orally once daily for 12 weeks.
Study: NCT05190523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets orally once daily for 12 weeks.
Study: NCT06471543
Drug: RN0361
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution
Study: NCT06283121
Drug: SOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy phase: Oxaliplatin 130 mg，i.v., D1 and D3, 3 weeks per cycle; Tegafur 40\~60mg b.i.d. p.o. D1\~D14; 3 weeks per cycle
Study: NCT06615830
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive the standard first-line chemotherapy (chosen among Gemcitabine-Abraxane, or Abraxane-Gemcitabine-FOLFOX or FOLFIRINOX, based on the clinical judgement of the treating oncologist) until disease progression.
Study: NCT06615830
Drug: Organoid-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon disease progression confirmed radiologically, the patients will receive second-line chemotherapy. Second-line chemotherapy will be selected among the most promising effective drug (or drug regimens) as predicted in vitro by their benchmarking on patient-derived organoids.
Study: NCT05259904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
Study: NCT06274853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT04849013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs
Study: NCT05663372
Drug: Efez 50 mg eplerenone film-coated tablets
Normalized name: eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
Study: NCT05663372
Drug: INSPRA® 50 mg eplerenone film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
Study: NCT06396637
Drug: Sapropterin Dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sapropterin Dihydrochloride: 20mg/kg, qd
Study: NCT04937829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06613269
Drug: 68Ga-NY104 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-NY104 PET/CT will be performed at baseline, 6 months, 12 months, and 24 months after radiation therapy if the tumor is under control. If CT or MRI shows any suspicious recurrence or metastasis, 68Ga-NY104 PET/CT can be performed at the decision of the urology oncologist or radiation oncologist.~The scan begins 1 hour after intravenous injection of 68Ga-NY104.
Study: NCT06613269
Drug: 18F-FDG PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-FDG PET/CT will be performed at baseline and 6 months after radiation therapy. The scan begins 1 hour after intravenous injection of 18F-FDG.
Study: NCT06613269
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy will be delivered to patients to control the tumor. Possible regimen includes targeted therapy alone, immunotherapy alone, and targeted therapy combined with immunotherapy. The treatment regimen will be decided according to the urology oncologist.
Study: NCT06404541
Drug: Dexamethasone, tobramycin, netilimicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose
Study: NCT05824858
Drug: LY3537982
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03070691
Drug: LDE225B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream, 2x daily
Study: NCT03070691
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream, 2x daily
Study: NCT06446388
Drug: QLS31905
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous infusion.
Study: NCT06592222
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT06590857
Drug: RYZ101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ac-225
Study: NCT06446388
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, oral, bid, D1-D14
Study: NCT04737850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with no active pharmaceutical ingredient
Study: NCT05303935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
Study: NCT05389709
Drug: Iberogast (STW5-II, BAY98-7410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey without any intervention assigned in the study.
Study: NCT05359068
Drug: SPH3127 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet
Study: NCT05359068
Drug: SPH3127 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets
Study: NCT05359068
Drug: SPH3127 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets
Study: NCT06597019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Study: NCT06604117
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who opt for this group will receive guideline-recommended conventional lipid-lowering therapy. For those with a history of ischemic stroke (IS), myocardial infarction (MI), acute coronary syndrome within the past year, symptomatic peripheral artery disease, or two or more high-risk factors, the target LDL-C level will be set at 1.4 mmol/L. For other IS participants, the LDL-C target will be set at 1.8 mmol/L. All participants will receive moderate-intensity statin therapy as the primary treatment. If LDL-C levels are not adequately controlled, ezetimibe will be added. If lipid levels remain unsatisfactory, the addition of PCSK9 inhibitors will be considered. Moderate-intensity statins are defined as atorvastatin 10-20 mg or rosuvastatin 5-10 mg.
Study: NCT06443255
Drug: Cociane hydrochloride 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 4% cocaine
Study: NCT06443255
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of saline 0.9%
Study: NCT05118360
Drug: ASC41 2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg of ASC41 orally once daily for 52 weeks
Study: NCT05118360
Drug: ASC41 4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg of ASC41 orally once daily for 52 weeks
Study: NCT05118360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo orally once daily for 52 weeks.
Study: NCT06121505
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
Study: NCT03680976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
Study: NCT06239714
Drug: SGB-3403
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Study: NCT04862884
Drug: HRS4800 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Drug: HRS4800 tablets Low-dose group, single oral administration~2. Drug: HRS4800 tablets Low-medium dose group, single oral administration~3. Drug: HRS4800 tablets medium -dose group, single oral administration~4. Drug: HRS4800 tablets Medium and high dose group, single oral administration~5. Drug: HRS4800 tablets High-dose group, single oral administration
Study: NCT04862884
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Drug: placebo Low-dose group, single oral administration~2. Drug: placebo Low-medium dose group, single oral administration~3. Drug: placebo medium -dose group, single oral administration~4. Drug: placebo Medium and high dose group, single oral administration~5. Drug: placebo High-dose group, single oral administration
Study: NCT05291052
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
Study: NCT06173596
Drug: ALXN2080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ALXN2080 orally.
Study: NCT05081336
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin +/- ezetimib +/- Alirocumab
Study: NCT00002194
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002194
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05270928
Drug: IBI346
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI346 Antibody and IBI346 CAR-T cell injection
Study: NCT05132569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral
Study: NCT04797442
Drug: WST01 strain product
Normalized name: BCG, live, Tice strain Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5\*10\^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)
Study: NCT04797442
Drug: placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)
Study: NCT05815082
Drug: FOLFOX chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
Study: NCT06355479
Drug: OsrHSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Serum Albumin from Oryza Sativa
Study: NCT06355479
Drug: Plasbumin®-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (Human) 20%, USP
Study: NCT06588010
Drug: OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st phase: 1 capsule per day of placebo for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of placebo for 10 consecutive days each month for three months.~Then 2nd phase: 1 capsule a day of OM-89, for 90 consecutive days followed by a period of 90 days without treatment, then one capsule a day of OM-89 6mg for 10 consecutive days each month for three months.
Study: NCT06260891
Drug: 25 mg/day zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of zinc as zinc gluconate taken orally once a day
Study: NCT06260891
Drug: 40 mg/day zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of zinc as zinc gluconate taken orally once a day
Study: NCT06678165
Drug: YOLT-204
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group will receive YOLT-204 on day0
Study: NCT06463717
Drug: Transplant, Autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan followed by autologous stem cell transplantation
Study: NCT06368141
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
Study: NCT04134026
Drug: HIF-PHI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug will be dosed orally three times a week.
Study: NCT01556152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for 28 Days
Study: NCT06412926
Drug: BAY 44-4400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet, oral use
Study: NCT04595266
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.~Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1
Study: NCT05523570
Drug: HNC364
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 subjects (both male and female) to receive 20 mg HNC364 intramuscular administration to evaluate the safety and tolerability of HNC364 injectable suspension. Then 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 20 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
Study: NCT05523570
Drug: HNC364
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 40 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
Study: NCT05523570
Drug: HNC364
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 60 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.